Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11GlobeNewsWire • 06/03/21
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development UpdateGlobeNewsWire • 05/13/21
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology AssociationGlobeNewsWire • 05/13/21
Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of ImmunologistsGlobeNewsWire • 04/27/21
Equillium's Itolizumab Shows Encouraging Safety, Tolerability Profile In Systemic Lupus Erythematosus StudyBenzinga • 03/31/21
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus PatientsGlobeNewsWire • 03/30/21
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development UpdateGlobeNewsWire • 03/24/21
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow TransplantationGlobeNewsWire • 03/15/21
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital ExperienceGlobeNewsWire • 02/12/21
Equillium Announces the Appointment of Katherine Xu to the Board of DirectorsGlobeNewsWire • 02/09/21
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital ExperienceGlobeNewsWire • 01/22/21
Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual Meeting and ExpositionGlobeNewsWire • 12/07/20
Equillium's stock tumbles after decision to not initiate late-stage trial of COVID-19 treatmentMarket Watch • 11/25/20
Equillium Reports Third Quarter 2020 Financial Results and Business HighlightsGlobeNewsWire • 11/10/20
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host DiseaseGlobeNewsWire • 11/06/20
Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus ErythematosusGlobeNewsWire • 11/04/20